# Larazotide Acetate, Answered: Your Top Questions Reviewed **By TelosRX Editorial Team** · 2026-09-24 **Larazotide acetate is a gut-specific synthetic peptide studied for its ability to tighten intestinal tight junctions — the protein seals that keep the gut lining intact. [TelosRX](https://telosrx.com)'s clinical team breaks down what the research actually shows about this emerging gut-barrier compound.** If you've searched "leaky gut peptide" or "what tightens gut junctions," larazotide is likely a name you've encountered. It's one of the few compounded peptides with human trial data specifically targeting intestinal permeability. Here's what those trials found. ## Larazotide Acetate, Answered: What It Is ### What exactly is larazotide acetate? Larazotide acetate (INN-202) is a synthetic, eight-amino-acid peptide derived from human fetal zonulin — a protein that regulates tight-junction permeability in the gut. It works by blocking zonulin from opening tight junctions, effectively keeping the gut barrier sealed when it would otherwise loosen. It acts locally and is not significantly absorbed systemically. Larazotide has been studied primarily by 9 Meters Biopharma in Phase 2 and Phase 3 trials focused on celiac disease. As of 2026, larazotide acetate is **not FDA-approved** for any indication. It is not an FDA-approved drug. ### Is larazotide actually a peptide? Yes. Larazotide is a synthetic peptide — eight amino acids in a single chain (Gly-Gly-Val-Leu-Val-Gln-Pro-Gly). It is structurally derived from a naturally occurring human protein but is synthesized for research and clinical use. It is distinct from collagen peptides or dietary supplement peptides — it is a pharmaceutical-grade compounded compound. ## How Larazotide Works: The Tight-Junction Mechanism ### What are tight junctions, and why do they matter? Tight junctions are protein "seals" between intestinal epithelial cells. When functioning normally, they allow nutrients through while blocking toxins, undigested food particles, and pathogens. When they loosen — sometimes called "increased intestinal permeability" — inflammatory molecules can cross into the bloodstream. Zonulin is a key regulator of this loosening process. In celiac disease and certain inflammatory gut conditions, zonulin levels are elevated, which drives tight-junction opening. Larazotide acts as a zonulin antagonist — it blocks zonulin's signal to the tight-junction complex. ### Does larazotide actually close leaky junctions? In preclinical research and Phase 2 trial data, yes. A 2020 review in the _American Journal of Physiology — Gastrointestinal and Liver Physiology_ summarized the mechanism: larazotide stabilizes tight junctions, reduces MLC-2 phosphorylation (a molecular marker of junction loosening), and restores barrier function in cell and animal models. A Phase 2 celiac trial showed reduced GI symptoms in patients who were already on a gluten-free diet but remained symptomatic. The FDA has not approved larazotide based on this data, and Phase 3 research is ongoing. More recent [PMC research (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12561949/) confirmed larazotide's protective effect on intestinal epithelial integrity by stabilizing tight junctions and reducing MLC-2 phosphorylation in additional models. ## What Conditions Is Larazotide Studied For? Condition Research Stage Key Finding Celiac disease Phase 3 trial (ongoing/completed) Phase 2 showed reduced GI symptoms vs placebo in symptomatic patients on a gluten-free diet Intestinal permeability / leaky gut Preclinical + Phase 2 Reduces permeability markers in cell and animal models; human data emerging IBS with intestinal permeability Early/mechanistic research Mechanistically plausible for IBS-D subtype; limited human-specific data COVID-19-associated gut permeability Investigational Studied for barrier protection in acute illness; early-stage only Larazotide is **not FDA-approved for any of these conditions**. All applications are based on research context, not regulatory approval. ## Side Effects and Safety: What the Research Shows ### What are the known side effects of larazotide acetate? In Phase 2 trials, larazotide acetate was generally well-tolerated. The most commonly reported events were mild GI symptoms — headache, nausea, and abdominal discomfort — at rates broadly similar to placebo in most studies. No serious adverse events were attributed directly to larazotide. Because larazotide remains in the gut (minimal systemic absorption), the risk of systemic side effects appears low based on current data. However, as a compound that is not FDA-approved, long-term safety in large populations is not yet established. ### Can larazotide be combined with other gut-health peptides? This is an active area of clinical interest. BPC-157 is studied for GI mucosal repair and inflammation reduction; KPV targets mucosal anti-inflammatory pathways. These mechanisms are distinct from larazotide's tight-junction focus and could theoretically be complementary. Whether stacking them offers additive benefit isn't established in human trials. Any multi-peptide protocol should be reviewed by a licensed provider. Our guides on [KPV for gut health and IBD](https://www.telosrx.com/blogs/peptides/kpv-peptide-gut-health-ibd-research) and [BPC-157 peptide research](https://www.telosrx.com/blogs/peptides/bpc-157-peptide-patient-guide-pcac-2026) cover those compounds in more depth. ## Access and Evaluation: How TelosRX Approaches Larazotide ### Can I get larazotide through TelosRX? Larazotide acetate is a compounded peptide that is **not FDA-approved**. Access through TelosRX is **subject to medical approval by a licensed provider** through an asynchronous evaluation — there are no live consultation calls required. Your evaluation is reviewed at your pace by a licensed clinician. ### How is larazotide administered? In clinical trials, larazotide acetate was administered orally in capsule form, typically 0.5mg to 2mg three times daily with meals. The oral route is central to its gut-targeted mechanism — it stays in the GI tract and does not require injection. Compounded formulations may vary; your provider review will address specific protocol details. ### Is larazotide right for everyone with gut symptoms? No. Larazotide is specifically studied for conditions involving tight-junction dysfunction and elevated zonulin activity. Not all GI symptoms have this as the root cause. A proper evaluation with a licensed provider is the right starting point for determining whether larazotide aligns with your clinical picture. Explore [TelosRX's peptide research hub](https://www.telosrx.com/blogs/peptides) for more context, or start your private evaluation at [TelosRX](https://telosrx.com). ## Frequently Asked Questions ### What is larazotide acetate used for? Larazotide acetate is studied primarily for celiac disease and conditions involving intestinal permeability. It works by blocking zonulin-mediated tight-junction loosening in the gut. It is not FDA-approved for any indication and is classified as an investigational compounded peptide. ### How does larazotide differ from BPC-157 for gut health? BPC-157 is studied for GI mucosal repair — promoting tissue healing, reducing inflammation, and improving blood flow to gut tissue. Larazotide is more precisely targeted at tight-junction integrity, preventing the gut barrier from becoming permeable in the first place. Different mechanisms, potentially complementary, but human stacking data is limited. ### Is larazotide acetate a natural compound? Larazotide is derived from human fetal zonulin — a naturally occurring protein — but the peptide itself is synthetically produced. It is not found in food, supplements, or over-the-counter products. It is a pharmaceutical-grade compounded peptide. ### Does larazotide work for IBS? Preclinical and early Phase 2 research supports larazotide's mechanism in reducing intestinal permeability, which can contribute to IBS-D symptoms. However, there are no completed IBS-specific trials for larazotide. Any use would be investigational compounded use, subject to provider evaluation and approval. ### What does the research say about larazotide for celiac disease? Phase 2 clinical data showed larazotide acetate reduced GI symptoms in celiac patients on a gluten-free diet who remained symptomatic. Phase 3 trials have concluded enrollment. Larazotide does not replace a gluten-free diet and has not been FDA-approved for celiac disease — it is studied as a potential adjunct approach. ### Is larazotide acetate safe long-term? Long-term safety data in large populations isn't yet established, as larazotide hasn't received FDA approval. Phase 2 trials showed a tolerability profile similar to placebo for short-term use. As with all investigational compounded compounds, use should be subject to evaluation and monitoring by a licensed provider. _TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service._ Start your private evaluation at [TelosRX](https://telosrx.com). **Tags:** celiac, gut health, intestinal permeability, larazotide, leaky gut, peptides, tight junctions --- > Source: [Telos RX](https://www.telosrx.com/blogs/peptides/larazotide-acetate-peptide-guide)